BI-1701963 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase I drugs for Lung Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-1701963 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-1701963 is under development for the treatment of KRAS mutated advanced or metastatic solid tumors including lung adenocarcinoma, non-small cell lung cancer, metastatic pancreatic cancer, metastatic cholangiocarcinoma and metastatic colorectal cancer. It is administered through oral route as a film coated tablet. The drug candidate acts by targeting son of sevenless homolog 1 (SOS1).
For a complete picture of BI-1701963’s drug-specific PTSR and LoA scores, buy the report here.